-
Je něco špatně v tomto záznamu ?
Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions
P. Dundr, K. Simon, K. Němejcová, M. Bártů, I. Tichá, R. Michálková, R. Jakša, Z. Věcková, O. Kodet,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV16-30954A
MZ0
CEP - Centrální evidence projektů
- MeSH
- imunohistochemie MeSH
- lidé středního věku MeSH
- lidé MeSH
- melanocyty metabolismus patologie MeSH
- melanom krev patologie MeSH
- nádorové biomarkery metabolismus MeSH
- nádory kůže krev patologie MeSH
- prognóza MeSH
- stathmin metabolismus MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
In several solid tumors, an increased stathmin expression is associated with both poor prognosis and resistance to certain chemotherapy types. However, the data regarding melanocytic lesions are very limited. The goals of our study are as follows: the assessment of stathmin expression in benign and malignant melanocytic lesions, and the significance of its expression for the differential diagnostics between benign and malignant lesions; the analysis of the prognostic significance of stathmin expression in melanoma; and the evaluation of stathmin expression in melanoma and melanoma metastases with respect to possible therapeutic targeting. Immunohistochemical analysis of stathmin expression was done in 323 melanocytic lesions, including 205 primary cutaneous melanomas, 60 melanoma metastases, and 58 melanocytic nevi. Stathmin expression was found in all analyzed groups of melanocytic lesions. Using the H-scoring system, the observed intensity of expression was as follows: melanocytic nevi: 146.1 (mean) and 150 (median); melanomas: 116.7 (mean) and 110 (median); and melanoma metastases: 136.8 (mean) and 140 (median). The stathmin expression was significantly lower in the cohort of primary melanomas when compared with metastases and nevi (P=0.001). The stathmin expression showed no prognostic significance. The high stathmin expression in melanoma suggests that stathmin might be a promising marker for therapeutic targeting in ongoing clinical trials. Compared with several other solid tumors, stathmin expression in melanoma showed no prognostic significance. The potential use of stathmin expression in differential diagnostics is limited by its common expression, and despite the statistically significant differences between nevi and melanoma, it may not be used in this setting.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028083
- 003
- CZ-PrNML
- 005
- 20190823095850.0
- 007
- ta
- 008
- 190813s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/CMR.0000000000000550 $2 doi
- 035 __
- $a (PubMed)30422880
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dundr, Pavel $u Institute of Pathology.
- 245 10
- $a Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions / $c P. Dundr, K. Simon, K. Němejcová, M. Bártů, I. Tichá, R. Michálková, R. Jakša, Z. Věcková, O. Kodet,
- 520 9_
- $a In several solid tumors, an increased stathmin expression is associated with both poor prognosis and resistance to certain chemotherapy types. However, the data regarding melanocytic lesions are very limited. The goals of our study are as follows: the assessment of stathmin expression in benign and malignant melanocytic lesions, and the significance of its expression for the differential diagnostics between benign and malignant lesions; the analysis of the prognostic significance of stathmin expression in melanoma; and the evaluation of stathmin expression in melanoma and melanoma metastases with respect to possible therapeutic targeting. Immunohistochemical analysis of stathmin expression was done in 323 melanocytic lesions, including 205 primary cutaneous melanomas, 60 melanoma metastases, and 58 melanocytic nevi. Stathmin expression was found in all analyzed groups of melanocytic lesions. Using the H-scoring system, the observed intensity of expression was as follows: melanocytic nevi: 146.1 (mean) and 150 (median); melanomas: 116.7 (mean) and 110 (median); and melanoma metastases: 136.8 (mean) and 140 (median). The stathmin expression was significantly lower in the cohort of primary melanomas when compared with metastases and nevi (P=0.001). The stathmin expression showed no prognostic significance. The high stathmin expression in melanoma suggests that stathmin might be a promising marker for therapeutic targeting in ongoing clinical trials. Compared with several other solid tumors, stathmin expression in melanoma showed no prognostic significance. The potential use of stathmin expression in differential diagnostics is limited by its common expression, and despite the statistically significant differences between nevi and melanoma, it may not be used in this setting.
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melanocyty $x metabolismus $x patologie $7 D008544
- 650 _2
- $a melanom $x krev $x patologie $7 D008545
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a nádory kůže $x krev $x patologie $7 D012878
- 650 _2
- $a stathmin $x metabolismus $7 D050777
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Simon, Karol $u Institute of Pathology.
- 700 1_
- $a Němejcová, Kristýna $u Institute of Pathology.
- 700 1_
- $a Bártů, Michaela $u Institute of Pathology.
- 700 1_
- $a Tichá, Ivana $u Institute of Pathology.
- 700 1_
- $a Michálková, Romana $u Institute of Pathology.
- 700 1_
- $a Jakša, Radek $u Institute of Pathology.
- 700 1_
- $a Věcková, Zuzana $u Institute of Pathology.
- 700 1_
- $a Kodet, Ondřej $u Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General University Hospital in Prague. Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00003323 $t Melanoma research $x 1473-5636 $g Roč. 29, č. 2 (2019), s. 157-162
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30422880 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823100105 $b ABA008
- 999 __
- $a ok $b bmc $g 1433232 $s 1066543
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 29 $c 2 $d 157-162 $e - $i 1473-5636 $m Melanoma research $n Melanoma Res $x MED00003323
- GRA __
- $a NV16-30954A $p MZ0
- LZP __
- $a Pubmed-20190813